Early Intratracheal Instillation of Budesonide Using Surfactant as a Vehicle to Prevent Chronic Lung Disease in Preterm Infants: A Pilot Study

No abstract is available for this paper.

• Publication year

  2008

• Venue

  Pediatrics

• Publication date

  2008-05-01

• Fields of study

  Medicine

• Identifiers
  DOI 10.1542/peds.2007-1973PMID 18426851
• External record

  Open on Semantic Scholar

• Source metadata

  Semantic Scholar, PubMed

• No claims are published for this paper.

• No concepts are published for this paper.

• Artificial surfactant therapy for hyaline membrane disease

  2006cited by this paper
• Topical and systemic glucocorticoid potencies of budesonide and beclomethasone dipropionate in man

  2004cited by this paper
• Outcomes at school age after postnatal dexamethasone therapy for lung disease of prematurity.

  2004cited by this paper
• Simultaneous quantification of budesonide and its two metabolites, 6beta-hydroxybudesonide and 16alpha-hydroxyprednisolone, in human plasma by liquid chromatography negative electrospray ionization tandem mass spectrometry.

  2003cited by this paper
• Inhaled versus systemic corticosteroids for preventing chronic lung disease in ventilated very low birth weight preterm neonates.

  2003cited by this paper
• Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants.

  2003cited by this paper
• Transport and local metabolism of budesonide and fluticasone propionate in a human bronchial epithelial cell line (Calu-3).

  2002cited by this paper
• CoASH and CoASSG Levels in Lungs of Hyperoxic Rats as Potential Biomarkers of Intramitochondrial Oxidant Stresses

  2002cited by this paper
• Intratracheal Administration Of Glucocorticoids Using Surfactant As A Vehicle

  2002cited by this paper
• Surfactant and corticosteroid effects on lung function in a rat model of acute lung injury

  2001cited by this paper
• Note: dissolution of aerosol particles of budesonide in Survanta, a model lung surfactant.

  2001cited by this paper
• Drug solubilization in lung surfactant.

  2000cited by this paper
• Budesonide inhalation suspension: a review of its use in infants, children and adults with inflammatory respiratory disorders.

  2000cited by this paper
• Early postnatal (<96 hours) corticosteroids for preventing chronic lung disease in preterm infants.

  2000cited by this paper
• Effect of budesonide and salbutamol on surfactant properties.

  2000cited by this paper
• Early Postnatal Dexamethasone Therapy for the Prevention of Chronic Lung Disease

  1999cited by this paper
• Early inhaled glucocorticoid therapy to prevent bronchopulmonary dysplasia.

  1999cited by this paper
• The role of pulmonary inflammation in the development of pulmonary hypertension in newborn with meconium aspiration syndrome (MAS)

  1999cited by this paper
• Liver enzyme elevations in patients treated with traditional Chinese medicine.

  1999cited by this paper
• Early dexamethasone therapy in preterm infants: a follow-up study.

  1998cited by this paper
• Reversible fatty acid conjugation of budesonide. Novel mechanism for prolonged retention of topically applied steroid in airway tissue.

  1998cited by this paper
• Efficacy of sequential early systemic and inhaled corticosteroid therapy in the prevention of chronic lung disease of prematurity

  1998cited by this paper
• Surfactant versus Saline as a Vehicle for Corticosteroid Delivery to the Lungs of Ventilated Rabbits

  1998cited by this paper
• Early postnatal dexamethasone therapy for the prevention of chronic lung disease in preterm infants with respiratory distress syndrome: a multicenter clinical trial.

  1997cited by this paper
• The kidney and urinary tract

  1996cited by this paper
• Efficiency of aerosol medication delivery from a metered dose inhaler versus jet nebulizer in infants with bronchopulmonary dysplasia

  1996cited by this paper
• Relationship between lung tissue and blood plasma concentrations of inhaled budesonide.

  1993cited by this paper
• Delivery of micronized budesonide suspension by metered dose inhaler and jet nebulizer into a neonatal ventilator circuit

  1992cited by this paper
• Delivery of therapeutic aerosols to intubated babies.

  1992cited by this paper
• Evaluation of techniques for delivery of steroids to lungs of neonates using a rabbit model.

  1992cited by this paper
• Influence of perinatal conditions on C-reactive protein production.

  1992cited by this paper
• Pulmonary surfactant as a vehicle for intratracheal delivery of technetium sulfur colloid and pentamidine in hamster lungs.

  1991cited by this paper
• Dexamethasone therapy in neonatal chronic lung disease: an international placebo-controlled trial. Collaborative Dexamethasone Trial Group.

  1991cited by this paper
• Early postnatal dexamethasone therapy in premature infants with severe respiratory distress syndrome: a double-blind, controlled study.

  1990cited by this paper
• A controlled trial of dexamethasone in preterm infants at high risk for bronchopulmonary dysplasia.

  1989cited by this paper
• Localization of surfactant in neonatal lung after exogenous administration.

  1987cited by this paper
• Controlled trial of dexamethasone in respirator-dependent infants with bronchopulmonary dysplasia.

  1985cited by this paper
• Kinetics of the epimeric glucocorticoid budesonide

  1984cited by this paper
• Controlled trial of dexamethasone therapy in infants with bronchopulmonary dysplasia.

  1983cited by this paper
• Development of new glucocorticosteroids with a very high ratio between topical and systemic activities.

  1982cited by this paper
• Statistical methods for rates and proportions

  1973cited by this paper
• Physical chemistry of surfaces

  1960cited by this paper

• Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants.

  2026cites this paper
• Efficacy of pulmonary surfactant with budesonide in infants born at or less than 28 weeks’ gestation: a systematic review and meta-analysis

  2025cites this paper
• Early Intratracheal Budesonide to Reduce Bronchopulmonary Dysplasia in Extremely Preterm Infants: The Budesonide in Babies (BiB) Randomized Clinical Trial.

  2025cites this paper
• Airway Administration of Budesonide Combined With Pulmonary Surfactant to Prevent Bronchopulmonary Dysplasia in Preterm Infants: A Systematic Review and Meta‐Analysis

  2025cites this paper
• Recent Advances in the Management of Bronchopulmonary Dysplasia

  2025cites this paper
• Comparative Efficacy and Safety Profile of the Combination of Pulmonary Surfactant and Budesonide vs. Surfactant Alone in the Management of Neonatal Respiratory Distress Syndrome: An Updated Meta-Analysis

  2025cites this paper
• Current and Emerging Therapies for Prevention and Treatment of Bronchopulmonary Dysplasia in Preterm Infants

  2025cites this paper
• Efficacy of pulmonary surfactant with budesonide in premature infants: A systematic review and meta-analysis

  2025cites this paper
• Efficacy of intratracheal budesonide plus surfactant vs. Surfactant alone on bronchopulmonary dysplasia in preterm Infants: A meta-analysis of randomized controlled trials.

  2025cites this paper
• Thermodynamic and Structural Study of Budesonide—Exogenous Lung Surfactant System

  2024cites this paper
• Intratracheal Budesonide Mixed With Surfactant for Extremely Preterm Infants: The PLUSS Randomized Clinical Trial.

  2024cites this paper
• Surfactant therapy - The conundrum of which infant should be given, when, which drug in what dose via which route of administration?

  2024cites this paper
• Endotracheal Surfactant and Budesonide Combination Therapy in Neonatal Acute Respiratory Distress Syndrome due to Late-Onset Sepsis

  2024cites this paper
• A complex inflammatory mix: chorioamnionitis, antenatal steroids and early postnatal budesonide

  2024cites this paper
• Corticosteroids for the prevention and treatment of bronchopulmonary dysplasia: an overview of systematic reviews.

  2024cites this paper
• Efficacy and safety of different inhaled corticosteroids for bronchopulmonary dysplasia prevention in preterm infants: A systematic review and meta-analysis.

  2024cites this paper
• Postnatal budesonide improved lung function in preterm lambs exposed to antenatal steroids and chorioamnionitis

  2024cites this paper
• Intratracheal budesonide mixed with surfactant to increase survival free of bronchopulmonary dysplasia in extremely preterm infants: study protocol for the international, multicenter, randomized PLUSS trial

  2023cites this paper
• Surfactant as a drug carrier.

  2023cites this paper
• Late surfactant administration after 48 hours of age in preterm neonates with respiratory insufficiency: a systematic review and meta-analysis

  2023cites this paper
• Simultaneous intratracheal administration of surfactant and budesonide in the prevention of bronchopulmonary dysplasia in the treatment of respiratory distress syndrome in premature infants

  2023influential citation
• Intratracheal Instillation of Budesonide–Surfactant for Prevention of Bronchopulmonary Dysplasia in Extremely Premature Infants

  2023cites this paper
• Pharmacotherapy of BPD: Current status & future perspectives.

  2023cites this paper
• Evaluation of intratracheal salbutamol effects in addition to surfactant in the clinical course of premature neonates with respiratory distress syndrome

  2023cites this paper
• Long-term Effects of Intratracheal Budesonide and Surfactant for the Prevention of Bronchopulmonary Dysplasia: A Narrative Review

  2023cites this paper
• Preterm lung and brain responses to mechanical ventilation and corticosteroids

  2023cites this paper
• Early Physiological and Adrenal Effects of Budesonide Mixed with Surfactant in Large Observational Preterm Cohort Study

  2022cites this paper
• Use of budesonide associated with a pulmonary surfactant to prevent bronchopulmonary dysplasia in premature newborns – A systematic review

  2022influential citation
• Current concepts of corticosteroids use for prevention of bronchopulmonary dysplasia.

  2022cites this paper
• Comparison of Intratracheal Administration of Surfactant With or Without Budesonide to Prevent Bronchopulmonary Dysplasia: A Parallel Randomized Pilot Study

  2022cites this paper
• The benefits, limitations and opportunities of preclinical models for neonatal drug development

  2022cites this paper
• The efficacy of intratracheal administration of surfactant and budesonide combination in the prevention of bronchopulmonary dysplasia

  2021cites this paper
• A systematic review and meta-analysis of pulmonary surfactant combined with budesonide in the treatment of neonatal respiratory distress syndrome.

  2021cites this paper
• Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part II. Inhaled corticosteroids alone or in combination with surfactants

  2021cites this paper
• Corticosteroids in the prevention and treatment of infants with bronchopulmonary dysplasia: Part I. systemic corticosteroids

  2021cites this paper
• Oxidative Stress and Respiratory Diseases in Preterm Newborns

  2021cites this paper
• Effectiveness and safety of early combined utilization of budesonide and surfactant by airway for bronchopulmonary dysplasia prevention in premature infants with RDS: A meta‐analysis

  2021cites this paper
• Presumed adrenal insufficiency in neonates treated with corticosteroids for the prevention of bronchopulmonary dysplasia

  2021cites this paper
• Diagnosis and management of bronchopulmonary dysplasia

  2021cites this paper
• Pulmonary surfactant: a unique biomaterial with life-saving therapeutic applications.

  2021cites this paper
• A Randomized Clinical Trial of Intratracheal Administration of Surfactant and Budesonide Combination in Comparison to Surfactant for Prevention of Bronchopulmonary Dysplasia

  2021cites this paper
• Systematic review of the healthcare cost of bronchopulmonary dysplasia

  2021cites this paper
• Strategies to protect surfactant and enhance its activity

  2021cites this paper
• Optimizing respiratory management in preterm infants: a review of adjuvant pharmacotherapies

  2021cites this paper
• Surfactant-Assisted Distal Pulmonary Distribution of Budesonide Revealed by Mass Spectrometry Imaging

  2021cites this paper
• The efficacy of intra-tracheal budesonide with surfactant in treatment of respiratory distress syndrome and prevention of bronchopulmonary dysplasia

  2021cites this paper
• Postnatal steroid management in preterm infants with evolving bronchopulmonary dysplasia

  2021cites this paper
• The Miracles of Surfactant: Less Invasive Surfactant Administration, Nebulization, and Carrier of Topical Drugs

  2021cites this paper
• Intra‐tracheal surfactant/budesonide versus surfactant alone: Comparison of two consecutive cohorts of extremely preterm infants

  2021cites this paper
• Efficacy of intratracheal budesonide-surfactant combined therapy in surfactant-insufficient rat lungs with lipopolysaccharide insult

  2021cites this paper
• Neurodevelopmental outcomes of infants with bronchopulmonary dysplasia

  2021cites this paper
• Assessment of Postnatal Corticosteroids for the Prevention of Bronchopulmonary Dysplasia in Preterm Neonates: A Systematic Review and Network Meta-analysis.

  2021cites this paper
• Blood metabolomics in infants enrolled in a dose escalation pilot trial of budesonide in surfactant

  2021cites this paper
• Dose-escalation trial of budesonide in surfactant for prevention of bronchopulmonary dysplasia in extremely low gestational age high-risk newborns (SASSIE)

  2020cites this paper
• The COVID-19 pandemic: a target for surfactant therapy?

  2020cites this paper
• Systemic and topical glucocorticoids to prevent BPD

  2020cites this paper
• What can exogenous surfactant provide in the fight against BPD?

  2020cites this paper
• Budesonide with surfactant decreases systemic responses in mechanically ventilated preterm lambs exposed to fetal intra-amniotic lipopolysaccharide

  2020cites this paper
• A Meta-Analysis of the Effects and Safety of Pulmonary Surfactants Combined with Budesonide in Bronchopulmonary Dysplasia

  2020cites this paper
• L’administration postnatale de corticostéroïdes pour prévenir ou traiter la dysplasie bronchopulmonaire chez les nouveau-nés prématurés

  2020cites this paper
• Phenotypes of Bronchopulmonary Dysplasia

  2020cites this paper
• Surfactant replacement therapy: from biological basis to current clinical practice

  2020cites this paper
• Intratracheal administration of budesonide with surfactant in very low birth weight infants to prevent bronchopulmonary dysplasia.

  2020cites this paper
• Postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia in preterm infants.

  2020cites this paper
• Recent advances in understanding and management of bronchopulmonary dysplasia

  2020cites this paper
• Glucocorticoid Treatment for Bronchopulmonary Dysplasia

  2020cites this paper
• Extended Pharmacopeial Characterization of Surfactant Aerosols Generated by a Customized eFlow Neos Nebulizer Delivered through Neonatal Nasal Prongs

  2020cites this paper
• Is inhaled budesonide a useful adjunct for the prevention or management of bronchopulmonary dysplasia?

  2020cites this paper
• Evidence base multi-discipline critical strategies toward better tomorrow for very preterm infants.

  2020cites this paper
• Pharmacological Therapies for the Prevention of Bronchopulmonary Dysplasia

  2020cites this paper
• Dose of budesonide with surfactant affects lung and systemic inflammation after normal and injurious ventilation in preterm lambs

  2020cites this paper
• Early Intratracheal Administration of Corticosteroid and Pulmonary Surfactant for Preventing Bronchopulmonary Dysplasia in Preterm Infants with Neonatal Respiratory Distress Syndrome: A Meta-analysis

  2019cites this paper
• Development and validation of an assay for quantifying budesonide in dried blood spots collected from extremely low gestational age neonates

  2019cites this paper
• Surfactant plus budesonide decreases lung and systemic inflammation in mechanically ventilated preterm sheep.

  2019influential citation
• Long-term effects of postnatal corticosteroids to prevent or treat bronchopulmonary dysplasia: Balancing the risks and benefits.

  2019cites this paper
• Alternatives to systemic postnatal corticosteroids: Inhaled, nebulized and intratracheal.

  2019cites this paper
• Drugs for the Prevention and Treatment of Bronchopulmonary Dysplasia.

  2019cites this paper
• Biophysical and chemical stability of surfactant/budesonide and the pulmonary distribution following intra-tracheal administration

  2019cites this paper
• Long‐term effects of the intratracheal administration of corticosteroids for the prevention of bronchopulmonary dysplasia: A meta‐analysis

  2019cites this paper
• Aerosol therapy in relation to retinopathy of prematurity in mechanically ventilated preterm infants

  2019cites this paper
• Surfactant plus budesonide decreases lung and systemic responses to injurious ventilation in preterm sheep.

  2019cites this paper
• Surfactant and budesonide for respiratory distress syndrome: an observational study

  2019cites this paper
• A new therapeutic regimen on prevention of Bronchopulmonary Dysplasia (BPD) in preterm infant

  2019cites this paper
• Meta-analysis of the efficacy of pulmonary surfactants combined with budesonide for the prevention of bronchopulmonary dysplasia

  2019cites this paper
• Effect of airway administration of budesonide for bronchopulmonary dysplasia in premature infants: A Systematic Review and Meta-Analysis

  2019cites this paper
• Bronchopulmonary dysplasia

  2018cites this paper
• Shaken or Stirred? Evaluating the combination of budesonide–surfactant for survival free of bronchopulmonary dysplasia

  2018cites this paper
• Effects of budesonide and surfactant in preterm fetal sheep.

  2018influential citation
• Extrem-Frühgeborene: Low-dose-Hydrocortison beeinflusst neurologische Entwicklung günstig

  2018influential citation
• Recomendaciones del VIII Consenso Clínico de SIBEN para la Displasia Broncopulmonar

  2018cites this paper
• Dexamethasone and outcome of meconium aspiration syndrome: Vijayapur, Karnataka experience

  2018cites this paper
• Recent Advances in Bronchopulmonary Dysplasia: Pathophysiology, Prevention, and Treatment

  2018cites this paper
• Efficacy and safety of pulmonary application of corticosteroids in preterm infants with respiratory distress syndrome: a systematic review and meta-analysis

  2018cites this paper
• A Time‐Based Analysis of Inflammation in Infants at Risk of Bronchopulmonary Dysplasia

  2018cites this paper
• 21 Bronchopulmonary Dysplasia

  2017cites this paper
• Late (≥ 7 days) inhalation corticosteroids to reduce bronchopulmonary dysplasia in preterm infants.

  2017cites this paper
• Advances in emerging treatment options to prevent bronchopulmonary dysplasia

  2017cites this paper
• Postnatal steroids in extreme preterm infants: Intra-tracheal instillation using surfactant as a vehicle.

  2017cites this paper
• The Fragility Index in a Cohort of Pediatric Randomized Controlled Trials

  2017cites this paper
• Intratracheal Administration of Budesonide‐Surfactant in Prevention of Bronchopulmonary Dysplasia in Very Low Birth Weight Infants: A Systematic Review and Meta‐Analysis

  2017cites this paper